Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
Research context
Syncona Limited appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Financial Services
- Industry
- Asset Management
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Syncona Limited is currently in a long term downtrend where the price is trading 11.7% below its 200 day moving average.
From a valuation standpoint, the stock is 66.2% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 17.9.
Finally, its free cash flow fell by 153.9% to $-8M since the same quarter in the previous year.
Based on the above factors, Syncona Limited gets an overall score of 1/5.